Abstract: The prevalence of cardiovascular disease (CVD) is higher in patients with schizophrenia than in the general population. We aimed to investigate whether atypical antipsychotics (AAP) increase the levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), thereby increasing the risk of CVD. The data were from inpatients aged 18-60 years with a diagnosis of schizophrenia according to ICD-10 at the Affiliated Brain Hospital of Nanjing Medical University who underwent physical examination between 1 October 2014 and 30 September 2016. A retrospective cohort study was used to analyse the correlation between AAP, Lp-PLA2 levels and the CVD risk (it was determined that Lp-PLA2 values >200 ng/mL were defined as high CVD risk) in patients treated with monotherapy, olanzapine, clozapine or quetiapine. Data were collected for 452 patients with eligible schizophrenia: 163 treated with clozapine, 186 treated with olanzapine, 47 treated with quetiapine and 56 receiving no medication. Compared with the no-medication patients, AAP administration in patients with olanzapine, clozapine or quetiapine had higher serum Lp-PLA2 levels when age, sex, BMI and fasting glucose level were matched. AAP were significantly associated with serum Lp-PLA2 level by Spearman's correlation coefficients. The results of logistic regression analysis showed that AAP administration was an independent factor of CVD risk when adjusted by potential confounding factors. This study is the first to confirm that AAP administration, especially clozapine and olanzapine, could increase Lp-PLA2 levels and CVD risk, independent of drug-induced weight gain in schizophrenia. The extent and the factors of increasing Lp-PLA2 level and CVD risk in olanzapine, clozapine and quetiapine are discrepant. The possible effects of AAP on Lp-PLA2 in schizophrenia patients are involved in pro-inflammatory cytokines and hormones.
The prevalence of cardiovascular disease (CVD) is higher in patients with schizophrenia than in the general population. CVDs, for example coronary heart disease and cerebrovascular disease, are the leading causes of death globally [1] . In addition to the known cardiovascular risk factors such as poverty, sedentary lifestyle, poor diet and reduced access to medical care, there is growing interest in the contribution of antipsychotics, especially the atypical antipsychotics (AAP) [2] .
Atypical antipsychotics are the first-line pharmacological intervention for schizophrenia. Oral AAP, especially olanzapine and clozapine, are associated with weight gain [3] , which can lead to overweight or obesity and other serious metabolic disorders including hyperlipidaemia and type II diabetes mellitus, substantially increasing the risk of CVD [4] . However, some schizophrenia patients with AAP may have few or none of the risk factors such as overweight and metabolic comorbidities, but still be at risk of CVD [5] . Among other pathophysiological factors that might increase CVD risk in patients with schizophrenia taking AAP, lipoprotein-associated phospholipase A2 (Lp-PLA2) plays an important role. This enzyme is an independent marker of coronary heart disease [6, 7] although it has not been proved as a useful target for therapy [8, 9] . The vast majority of studies have demonstrated a strong association with higher serum Lp-PLA2 values predicting the risk of subsequent cardiovascular events. Lp-PLA2, a member of the phospholipase A2 superfamily, is a Ca 2+ -independent protein produced primarily by macrophages. It circulates in the plasma in active form as a complex with lowdensity lipoprotein (LDL) and high-density lipoprotein (HDL). In plasma, approximately 80% of Lp-PLA2 bond to LDL with only around 10% bonding to HDL. LDL-associated Lp-PLA2 remains latent until LDL is oxidized. Lp-PLA2 cleaves the oxidized LDL into two bioactive compounds, lysophosphatidylcholine (lyso-PC) and oxidized non-esterified free fatty acids, which results in up-regulated inflammation in atherosclerotic plaques [10] , thereby increasing CVD risk. Lp-PLA2 testing is recommended in CVD risk Assessment Guidelines of Adult Treatment Panel III and the American Heart Association/Centers, and might be reasonable for cardiovascular risk Author for correspondence: Hong Xiao, Neuro-Psychiatric Institute, The Affiliated Brain Hospital of Nanjing Medical University, 264# Guangzhou Road, Nanjing, China (e-mail xhnkyy123@163.com). Hong Shen and Danyang Wu, as first authors, contributed equally to this study.
assessment in intermediate-risk asymptomatic adults [11, 12] . A threshold for increased cardiovascular risk at 200 ng/mL or above is defined as higher CVD risk [13] . As such, it is considered that among other pathophysiological factors that might increase CVD risk in the patients with schizophrenia taking AAP, Lp-PLA2 plays an important role. We suggested that AAP might increase the level of circulating Lp-PLA2 and thereby increase CVD risk in schizophrenia patients. However, no study has evaluated Lp-PLA2 serum concentration in schizophrenia patients treated with AAP. Therefore, this retrospective cohort study aimed to assess the association between atypical antipsychotic drug, Lp-PLA2 level and CVD risk in schizophrenia patients. Then, we verified firstly, whether AAP administration increased Lp-PLA2 level and CVD risk; secondly, whether AAP administration was associated with higher Lp-PLA2 levels; thirdly, whether AAP administration was an independent risk factor for CVD in the whole study population; and lastly, we wanted to find out whether AAP administration was a strong independent risk factor for CVD in subgroups stratified by sex, BMI or fasting serum glucose, ultimately clarifying the impact of AAP administration for Lp-PLA2 level and CVD risk in schizophrenia patients. In addition, we evaluated the association between Lp-PLA2 level, daily dose and medication duration of AAP administration.
Materials and Methods
Patients and study design. We used data from inpatients who had undergone physical examinations at the Affiliated Brain Hospital of Nanjing Medical University (NBH) from 1 October 2014 to 30 September 2016. We included schizophrenia patients with an ICD-10 diagnosis, having no symptoms of CVD and who had received olanzapine, quetiapine or clozapine therapy for more than 2 weeks, as well as schizophrenia patients who had taken no antipsychotics (the drug-na€ ıve patients) or were off psychiatric medication before blood sampling for at least 2 weeks (the drug-free patients). All the patients were Han Chinese. Exclusion criteria were as follows: patients who were aged <18 or >60 years; who were prescribed more than one or combinations of antipsychotics; and with any ongoing severe cardiovascular, hepatic or renal disease, diabetes mellitus, metabolic syndrome, use of lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors), systemic inflammatory disease (rheumatoid arthritis and lupus erythematosus) based on clinical and laboratory assessment and use of immunosuppressant drugs. All inpatients were non-smokers and not consuming alcohol during hospitalization. None were pregnant or breastfeeding.
We used the electronic medical record system in NBH to collect patients' clinical data on demographics, medical diagnoses, age of illness onset, illness duration, concomitant medications and detailed antipsychotics use (history of antipsychotics use, daily dose and duration of medication). The historical data of laboratory measurements including levels of Lp-PLA2, fasting serum glucose, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDLc) and low-density lipoprotein cholesterol (LDLc) were collected from the Laboratory Information System in NBH. Daily dose was calculated using the formula: daily dose = daily drug consumption (mg)/weight (kg). Because the patients in this study had no symptoms of CVD, Lp-PLA2 levels were used to assess CVD risk, and a cut-off value at 200 ng/mL or above was defined as high CVD risk [13] . The cohort study was based on data routine clinical care and administration. During hospitalization, most of the patients underwent physical examination once, the minority of patients twice or more than twice. All data were collected if the patients were eligible.
All data were collected by two independent observers, without any knowledge of this study. All study protocol and consent forms were in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving human beings, reviewed and approved by the Ethics Committee of NBH (Permit Number: 2014-KY051).
Laboratory measurements. The data of laboratory measurements were collected from the Laboratory Information System in NBH. The human serum levels of Lp-PLA2 were detected by a commercially available immunoturbidimetric assay (Norman, Nanjing, China) with NORMAN2 nephelometer measure. Fasting serum glucose, TG, TC, HDLc and low LDLc levels were measured with a Hitachi 7600 automatic biochemical analyser using Roche reagents (Roche Diagnostics, Mannheim, Germany) for glucose, TG and TC, and using SSUF reagents (SSUF, Shanghai, China) for LDLc and HDLc. All blood was drawn after a 12-hr fast.
Statistical analyses. The statistical analyses were carried out with the Statistical Package for Social Sciences (SPSS, version 19; IBM, Armonk, NY, USA). Descriptive analyses included the calculations of means, standard deviations (S.D.) for continuous variables and frequencies, and percentages for categorical variables. Demographic characteristics, therapeutic characteristics and laboratory measurements were compared using chi-square test or one-way ANOVA. All p values were two-tailed. The significance level was set at 0.05. Using Spearmen's correlation coefficients, we assessed potential associations between Lp-PLA2 levels in a continuous fashion and AAP administration, as well as other variables, such as age, sex, age of illness onset, illness duration, BMI, levels of fasting serum glucose, TC, TG, HDLc and LDLc. AAP administration [the no-medication (0), quetiapine (1), clozapine (2) and olanzapine (3)) and sex (male (0) and female (1)] were in a nominal fashion, and other variables were in a continuous fashion. These analyses were undertaken for the total group, also across categories of the CVD risk (Lp-PLA2: >200 ng/mL versus ≤200 ng/mL) and categories of AAP subgroups. In the AAP subgroups, duration of medication [0.50-0.75 months (1), 0.75-1.00 months (2), 1.00-2.00 months (3), 2.00-6.00 months (4), >6 months (5)] was defined as rank variables.
Possible associations of AAP administration and CVD risk in ordinal categories (Lp-PLA2: >200 ng/mL versus ≤200 ng/mL) were assessed using logistic regression modelling when other continuous/ nominal variables were taken into consideration. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported for both unadjusted and adjusted parameter estimates. Other variables included age, sex, age of illness onset, illness duration, BMI, levels of fasting serum glucose, TC, TG, HDLc and LDLc. AAP variable was divided into quintiles, with the first quintile serving as the referent category. The sex variable was divided into quintiles, with the last quintile serving as the referent category. Models were fitted using entry stepwise elimination.
After the logistic regression in the whole study population, we conducted serial logistic regression stratified by AAP administration, sex, BMI or glucose to further examine the possible associations of AAP administration and CVD risk, as well as identify independent associated factors of CVD risk in different conditions. Firstly, the whole study population was divided into quetiapine, clozapine, olanzapine and no-medication subgroups, or high BMI and low BMI subgroups, or high glucose and low glucose subgroups, respectively. Secondly, the stratification in BMI or glucose subgroups was based on a cut-off value with receiver operating characteristic (ROC) analysis. ROC curves were created by plotting the range of sensitivity and specificity pairs for BMI and glucose, with CVD risk as the classifier variable. To determine the threshold BMI and glucose, Youden's index was used to discriminate between high CVD risk patients (Lp-PLA2 > 200 ng/mL) and controls (Lp-PLA2 ≤ 200 ng/mL). When Youden's index reached the maximum value, the corresponding BMI and glucose were considered the optimum cut-off threshold. Then, it was defined that BMI (or glucose) >cut-off threshold as high BMI (or glucose) and BMI (or glucose) <cut-off threshold as low BMI (or glucose). Thirdly, the serial logistic regression in subgroups was analysed. ORs (95% CIs) were reported for both unadjusted and adjusted parameter estimates. All models were constructed using forced entry of all covariables, including age, sex, age of illness onset, illness duration, BMI, levels of fasting serum glucose, TC, TG, HDLc and LDLc. Daily dose and duration of medication were also considered as covariables in AAP administration subgroups (quetiapine, clozapine and olanzapine). Duration of medication was divided into quintiles, with the first quintile serving as the referent category.
Results
We collected data between 1 October 2014 and 30 September 2016. A total of 2680 case records of schizophrenia inpatients who received olanzapine, quetiapine, clozapine or no medication were reviewed. Four hundred and fifty-two patients who were eligible ( fig. 1 ) all provided written informed consent: 163 were treated with clozapine, 186 were treated with olanzapine, 47 were treated with quetiapine and 56 received no antipsychotics. The patients were mostly female (64.6%) with a mean age (S.D.) of 38.7 (10.9) years. The patients' demographic characteristics, therapeutic characteristics and laboratory measurements with or without AAP administration are presented in table 1. Overall, high CVD risk was found in 231 of 452 (51.1%) of the study cohort: 59.5% of patients treated with clozapine (p = 0.0000), 55.9% of patients treated with olanzapine (p = 0.0000), and 42.6% of patients treated with quetiapine (p = 0.0060). The incidence rates of high CVD risk in the patients with AAP administration were more than those of the patients who received no antipsychotics (17.9%). Moreover, the results of comparison showed that AAP-treated patients had higher serum Lp-PLA2 levels compared with the no-medication patients when age, sex, BMI and fasting glucose level were matched. There was a significant difference between the patients who received clozapine and the patients who received olanzapine, but not in the patients receiving quetiapine.
Spearman's correlation coefficients were used to assess the association between serum Lp-PLA2 levels and potential confounding factors in schizophrenia preferences as shown in fig. 2A . Overall, AAP administration was significantly associated with serum Lp-PLA2 levels (R = 0.190; p = 0.000). Other variables, such as male sex (R = 0.222; p = 0.000), high BMI (R = 0.278; p = 0.000), high levels of fasting serum glucose (R = 0.199; p = 0.000), TC (R = 0.105; p = 0.026), TG (R = 0.146; p = 0.002), LDLc (R = 0.167; p = 0.000) and low HDLc level (R = 0.124; p = 0.009), were also correlated to high Lp-PLA2 levels. In the high CVD risk subgroup, AAP administration was also significantly associated with serum Lp-PLA2 levels (R = 0.136; p = 0.039), while in the low CVD risk subgroup, AAP administration was not (R = 0.023; p = 0.735).
To assess associations of AAP administration and CVD risk, the results of logistic binary regression analysis are shown in table 2. After adjustment for covariables (i.e. age, sex, age of illness onset, illness duration, BMI, levels of fasting serum glucose, TC, TG, HDLc and LDLc), only AAP administration (quetiapine, clozapine and olanzapine), male sex, BMI and fasting glucose level remained significant.
The results of the logistic regression stratified by AAP further examined the association between CVD risk and AAP administration (table 2) . After adjustment, it was observed that in the olanzapine subgroup, there were three associated factors of CVD risk, including the sex BMI and fasting serum glucose level. Table 2 also shows the results of logistic regression stratified by sex, BMI or glucose. Firstly, after adjustment, independent associated factors of CVD risk were identified in sex subgroups; in males, only clozapine was the independent associated factor, while in females, there were four associated factors, including clozapine, olanzapine, BMI and glucose. Secondly, based on the results of the ROC curve analysis, the cut-off value of BMI (>25.65 kg/m 2 ) and glucose (>4.855 mmol/L) that caused high CVD risk was determined ( fig. 2B,C) . After determination of the cut-off value, the results of the logistic regressions across categories of BMI or glucose status showed that in the high BMI subgroup, olanzapine, clozapine and The results of receiver operating characteristic curve analysis, the cut-off value of BMI and fasting serum glucose level that caused high CVD risk were determined. (B) AUC in total group were 0.626 (p = 0.000). BMI of >25.42 kg/m 2 yielded the maximum Youden's index value at sensitivity of 43.64% and specificity of 78.64%. (C) AUC in total group were 0.594 (p = 0.001). The glucose level of >4.855 mmol/L was corresponding to maximal Youden's index at sensitivity of 45.89% and specificity of 72.73%. (D-F) The results of the comparison between high and low BMI, high and low glucose, and females and males in Lp-PLA2 levels in the whole study population, AAP and no-medication subgroups are shown. (D) There were significant differences between high and low BMI patients in the whole study population, clozapine and olanzapine subgroups. (E) The patients with high glucose level presented higher Lp-PLA2 levels than those with the low glucose level in the whole study population, clozapine and olanzapine subgroups. (F) The male patients had higher Lp-PLA2 levels compared with the female patients in the whole study population, clozapine, olanzapine and no-medication subgroups. (G) Lp-PLA2 levels and medication duration profiles in quetiapine, olanzapine, clozapine and no-medication subgroups are summarized.
The results of the comparisons between high and low BMI, high and low glucose and females and males in Lp-PLA2 levels are shown in fig. 2D -F. The male, high BMI and high glucose subgroups exhibited higher serum Lp-PLA2 levels compared to the counterparts in the whole study population, olanzapine and clozapine subgroups, and not in the quetiapine subgroup. Interestingly, after the comparisons in Lp-PLA2 levels by sex, BMI or glucose stratification, only the male patients showed higher serum Lp-PLA2 levels than the female patients in the group of untreated patients.
The association between Lp-PLA2 level, daily dose and duration of AAP medication was evaluated. Of note, the results of Spearman's correlation coefficients in the three AAP subgroups showed that higher Lp-PLA2 levels were associated with low-daily clozapine dose (R = 0.149, p = 0.063) and low-daily olanzapine dose (R = 0.187, p = 0.015), while there was no association between daily quetiapine dose and serum Lp-PLA2 level ( fig. 2A) . Lp-PLA2 level and medication duration profiles in the quetiapine, olanzapine, clozapine and nomedication subgroups are summarized in table 1 and fig. 2G . Lp-PLA2 levels waved and presented double peaks over time in the quetiapine, olanzapine and clozapine subgroups, but there was no significant difference in the quetiapine subgroup.
Discussion
The present study is the first to examine Lp-PLA2 levels that may underlie high CVD morbidity and mortality and may be associated with AAP administration in schizophrenia, using data from a 2-year retrospective cohort. Firstly, these results documented that AAP administration including olanzapine, clozapine and quetiapine could elevate serum Lp-PLA2 levels and increase the incidence rate of high CVD risk. Secondly, antipsychotics administration was the dominant factor of CVD risk when adjusted by potential confounding factors, that is age, sex, age of illness onset, illness duration, BMI, levels of fasting serum glucose, TC, TG, HDLc and LDLc. Thirdly, the results of logistic regression stratified by sex, BMI or glucose showed that AAP administration exhibited higher ORs of high CVD risk in the female, high BMI and the low glucose subgroups when compared to the male, low BMI and high glucose counterparts. The high BMI patients who received antipsychotics drugs including olanzapine, clozapine or quetiapine had more than 20 times odds of high CVD risk with the no-medication patients as reference category. Fourthly, the comparisons between subgroups stratified by sex, glucose level and weight showed that the male patients, the patients with high BMI or the patients with high level of fasting serum glucose presented with higher serum Lp-PLA2 levels in the whole study population, olanzapine and clozapine subgroups but not in the quetiapine subgroup. Finally, it was observed that Lp-PLA2 levels were associated with low-daily dose and presented double peaks over time in olanzapine and clozapine subgroups, but there was no significant difference in the quetiapine subgroup.
Atypical antipsychotic administration could elevate serum Lp-PLA2 levels and be an independent associated factor of CVD risk among the schizophrenia patients. Weight gain is an important side effect of AAP, especially in relation to olanzapine and clozapine. Generally, Lp-PLA2, involved in the metabolism of LDLc, is positively associated with BMI [14, 15] . It is recognized that BMI is the predictor of high Lp-PLA2 levels and CVD risk in the population [16] [17] [18] . Moreover, as mentioned above, AAP, especially, olanzapine and clozapine pose a higher risk of weight gain and type 2 diabetes. As such, initially, it was considered that the alteration in Lp-PLA2 levels was followed by the elevation of weight gain linked to atypical antipsychotic use. However, in this study, we found that AAP administration, including olanzapine, clozapine and quetiapine, could elevate serum Lp-PLA2 levels and the incidence rate of high CVD risk when BMI and the fasting serum glucose level were matched between the no-medication patients and the patients treated with AAP. This is the primary reason why we consider that AAP might increase serum Lp-PLA2 levels and the incidence rate of high CVD risk, independent of drug-induced weight gain. Furthermore, we focused on the association between AAP administration and serum Lp-PLA2 levels. The correlation analysis showed that AAP administration was significantly associated with serum Lp-PLA2 levels in the total group and the high CVD risk group, but not in the low CVD risk group. However, other variables such as sex, BMI, levels of fasting serum glucose and factors of lipid metabolism such as TC, TG, LDLc and HDLc level were also correlated to Lp-PLA2 levels. These complex interactions among Lp-PLA2 levels, weight gain and certain metabolic disorders from antipsychotic administration made it difficult to determine whether high Lp-PLA2 levels were due to AAP administration or drug-induced weight gain. To avoid the potential confounding effects of obesity and hyperglycaemia on serum Lp-PLA2 levels, we conducted logistic regression analysis to assess the associations of AAP administration and CVD risk when weight and certain metabolic biomarkers had been considered. After adjustment, AAP administration (quetiapine, clozapine and olanzapine) were still significantly associated with CVD risk. Quetiapine, clozapine and olanzapine all had more than three times higher OR of high CVD risk. Obviously, antipsychotic drugs were the dominant and independent factors of CVD risk, especially clozapine, which is first reported for AAP administration in schizophrenia patients and that is the second evidence to prove that AAP administration increasing CVD risk is a direct effect and not due to weight gain.
BMI is an unignorable associated factor of CVD risk in patients receiving AAP, especially clozapine and olanzapine. The comparison results of Lp-PLA2 levels show that high BMI patients were susceptible to higher Lp-PLA2 levels and CVD risk. It was notable that in the subgroup analysis according to BMI, AAP produced much greater OR of high CVD risk in the high BMI patients than in the low BMI patients. In the high BMI patients, the OR were 65.734 (olanzapine), 70.435 (clozapine) and 20.002 (quetiapine) with the no-medication group as reference category. Fat accumulation is the reason of the increased Lp-PLA2 levels in high BMI patients. Visceral fat accumulation plays important roles in LDL atherogenicity including increased LDL oxidation and smaller LDL particle size, and oxidative stress activating inflammation and cytokine expression [19] . Ox-LDL stimulates Lp-PLA2 expression in monocytes through the phosphatidylinositol 3-kinase and p38 mitogen-activating protein kinase pathways [20] . Nevertheless, our finding exhibited that AAP, especially clozapine and olanzapine, was an associated factor of CVD risk in low BMI patients. The ORs were 4.519 (olanzapine) and 6.448 (clozapine). The results offer a novel insight that BMI is not the predictor of high Lp-PLA2 levels; conversely, Lp-PLA2 levels are the predictor of weight gain. Thus, we speculate that AAP, especially olanzapine, clozapine and quetiapine, cause the adverse effects in terms of abnormal lipid metabolism including Lp-PLA2 increase and secondary to weight gain. Consequently, weight gain stimulates Lp-PLA2 expression. The progress may explain why AAP produced higher Lp-PLA2 levels and OR of high CVD risk in the high and low BMI patients and be another evidence that AAP administration increased CVD risk independent of druginduced weight gain.
The impacts of atypical antipsychotic administration on Lp-PLA2 levels and CVD risk were different in subgroups stratified by fasting serum glucose and sex. The finding of fasting serum glucose level analysis offered evidence that there was a positive correlation between Lp-PLA2 levels and glucose. The comparison results show that patients with high glucose level presented higher Lp-PLA2 levels than patients with low glucose level. Interestingly, AAP administration exhibited higher ORs of high CVD risk in the patients with low glucose level. In fact, hyperglycaemia and insulin resistance are the other side effects of long-term AAP use [21] . Some studies have offered generally consistent evidence that treatment of clozapine and olanzapine is associated with an increased risk of diabetes mellitus. Lp-PLA2 is also a type 2 diabetes mellitus (T2DM) predictor [22] . Lp-PLA2 activity significantly rose in patients of type 2 diabetes during the early stages of the disease. T2DM patients in whom Lp-PLA2 activity was elevated were also more likely to develop CAD than those without elevated levels [23] . Therefore, it is indicated that AAP tend to produce high CVD risk in the early stages of treatment and before hyperglycaemia.
Sex was found as an independent associated factor of CVD risk in the whole study cohort. The finding presented that the male patients had higher serum Lp-PLA2 levels than the female patients, which is consistent with previous reports of significant correlation between sex and Lp-PLA2 activity in the healthy Han population and the Dallas Heart Study [14, 24] . Oestrogen has a direct independent down-regulatory effect on Lp-PLA2 [25] [26] [27] , which might explain why male patients present higher Lp-PLA2 baseline levels than female patients, including schizophrenia patients. The results of adjusted logistic regression analysis show that only clozapine was the independent associated factor of CVD risk in male patients. In female patients, except for clozapine and olanzapine, BMI and glucose were associated factors of CVD risk. Moreover, compared with male patients, clozapine and olanzapine showed higher ORs of high CVD risk in the female patients. The ORs were 16.229 (olanzapine) and 25.500 (clozapine). It is remaindered that the female patients are prone to high CVD risk after receiving clozapine and olanzapine medication, despite of the male patients with higher Lp-PLA2 levels.
The association between Lp-PLA2 levels and daily dose and medication duration of atypical antipsychotic administration is likely to be a reference to medication administration. The relation between Lp-PLA2 levels and the medication duration and drug daily dose could not be ignored. Correlation analysis showed a negative correlation between daily olanzapine/clozapine dose and Lp-PLA2 levels, which indicates that the lower daily olanzapine/clozapine dose results in higher CVD risk among the patients.
Lp-PLA2 levels and medication duration profiles in quetiapine, olanzapine and clozapine subgroups were assessed. We found that Lp-PLA2 levels presented double peaks over time in the quetiapine (p > 0.05), olanzapine and clozapine subgroups. According to the interesting finding, we speculate that the first peak is produced due to low-dose AAP administration inducing high Lp-PLA2 levels in the early stages of treatment before hyperglycaemia and weight gain, and the second peak increasing is because of continuous elevation of Lp-PLA2 levels following drug-induced weight gain and other confounders after long-term treatment. Thus, we suggest that serum Lp-PLA2 levels should be measured when initiating and maintaining antipsychotic therapy in schizophrenia patients taking AAP, followed by early intervention, where appropriate.
The extent and the associated factors of increasing Lp-PLA2 levels and CVD risk in olanzapine, clozapine and quetiapine are discrepant. Nevertheless, olanzapine, clozapine and quetiapine all have impacts on serum Lp-PLA2 levels and CVD risk. The extent and the associated factors of these impacts are discrepant. Firstly, the means values of serum Lp-PLA2 levels increased in the three drug-treated patients compared with those without medication, but there were significant differences in clozapine and olanzapine-treated patients, while not in the quetiapinetreated patients. Moreover, the clozapine-treated patients (p = 0.0018) and the olanzapine-treated patients (p = 0.0024) had higher levels of serum Lp-PLA2 than the patients receiving quetiapine. Furthermore, the results show that 59.5% of patients treated with clozapine, 55.9% of patients treated with olanzapine and 42.6% of patients treated with quetiapine exhibited high CVD risk. The order of the OR of high CVD risk was clozapine (10.424) >olanzapine (7.522) >quetiapine (3.552). These results indicated that the extent of impacts was clozapine >olanzapine >quetiapine. Secondly, the results of the serial logistic regression stratified by, sex, BMI or glucose show that in each subgroup, including male and female patients, high and low BMI, and high and low glucose levels, clozapine and olanzapine were always the independent risk factors for the CVD. Only in the high BMI subgroup and the low glucose subgroup, quetiapine became the independent CVD risk after adjustment. The comparison results in Lp-PLA2 levels show that there were significant differences between males and females, high and low BMI, and high and low glucose subgroups in serum Lp-PLA2 levels in olanzapine-or clozapine-treated patients, but not in quetiapine-treated patients. The lines of data imply that quetiapine has a different impact on Lp-PLA2 levels from clozapine and olanzapine, which will help us find the mechanism of AAP-induced Lp-PLA2 levels and CVD risk.
There are several plausible mechanisms linking Lp-PLA2 with AAP administration. Indeed, Lp-PLA2 is actively secreted by intimal leucocytes, primarily macrophages, in response to known inflammatory cytokines, interleukin (IL)-1, IL-6 and tumour necrosis factor-alpha (TNF-a). Secreted Lp-PLA2 cleaves oxidized phosphatidylcholines (PC) from two possible sources: oxidized LDL or cells undergoing apoptosis or necrosis. The significant quantities of lyso-PC plus oxidized fatty acids (oxFAs) generated can lead to further leucocyte activation, including generation of reactive oxygen species (ROS), as well as further induction of apoptosis and necrosis. A vicious cycle is created in which Lp-PLA2 plays a central role [18, 28] . As such, Lp-PLA2 plays its key roles not just in lipid metabolism but also in initiating inflammation. Hence, it is speculated that the possible effects of AAP on Lp-PLA2 levels in the schizophrenia patients are involved in inflammation. Generally, AAP have multiple sites of action such as dopaminergic, serotonergic, cholinergic and histaminergic receptors; they exhibit different bioactivity on pro-inflammatory cytokines. Notwithstanding, the inflammatory cytokines of evidence here is contradictory, with some clinical studies showing suppression of the production of pro-inflammatory cytokines, some showing no change and some showing increased levels of cytokines after initiation of these medications [29] [30] [31] [32] . The literature suggests that antipsychotics (especially clozapine) consistently decreased peripheral IL-2 levels and increased sIL-2R and soluble tumour necrosis factor receptor (sTNF-R) levels [33, 34] . Clozapine therapy was also associated with an increase in peripheral TNF-a level [30] . Olanzapine increased the levels of TNF-a, IL-1 and IL-6 [35] [36] [37] , while the opposite was observed for quetiapine [37] [38] [39] [40] . The data indicated that AAP, such as olanzapine and clozapine, resulted in up-regulation of Lp-PLA2 via pro-inflammatory mediators, TNF-a, IL-1, IL-2 or IL-6 in the early stages of treatment.
Notably, AAP administration is known to influence the hypothalamo-hypophyseal-gonadal axis by inducing variable degrees of hyperprolactinaemia. High circulating prolactin (PRL) levels can cause reduced gonadal hormone levels (i.e. reduced oestrogen levels in women and reduced testosterone levels in men). Moreover, oestrogen is an important regulatory function in PRL secretion. AAP-induced hyperprolactinaemia is thought to account for high rates of diminished oestrogen levels in women with schizophrenia. It was well-known that oestrogens could decrease the Lp-PLA2 levels and activity. Nevertheless, clozapine, quetiapine and olanzapine were all called as PRL-sparing antipsychotics; they presented with a variety of symptoms. Piriu et al. [41] found decreased oestradiol levels and no statistically significant influence on PRL levels in men with schizophrenia treated with clozapine. Olanzapine, an antipsychotic with an intermediary D2R binding affinity, induced a moderate elevation of PRL levels [42, 43] . The preliminary study of Canuso et al. [44] found that most individuals treated with PRL-sparing potential antipsychotic (seven with olanzapine and one with clozapine) had peak oestradiol levels below normal reference values. Quetiapine induced virtually no PRL elevation and oestrogen across their full-dose range. Hence, hormones such as oestrogen and PRL are the other reasons why clozapine and olanzapine induced Lp-PLA2 elevation, which could explain that the female patients are prone to high CVD risk after receiving clozapine and olanzapine treatment.
Other mechanisms by which AAP administration influences the level of serum Lp-PLA2 may be associated with the role of polymorphisms in several candidate genes for antipsychotic-induced Lp-PLA2, such as PLA2G7, the possible roles of various neurotransmitters and neuropeptides in APP administration and the different degrees of AAP action on the serotonergic, dopaminergic, cholinergic, histaminergic and other neurotransmitter systems. These complex interactions between Lp-PLA2 levels and AAP should be investigated in future studies.
Conclusions
The present study is the first to confirm the hypothesis that AAP administration, such as clozapine, olanzapine and quetiapine, could increase Lp-PLA2 levels and CVD risk, independent of drug-induced weight gain in schizophrenia. It is speculated that low-daily dose AAP administration tends to produce high Lp-PLA2 levels in the early stages of treatment before hyperglycaemia. Moreover, Lp-PLA2 levels increased continuously following induced weight gain and other confounders after long-term treatment. The male patients, the patients with higher BMI or the patients with higher level of fasting serum glucose presented with higher Lp-PLA2 levels. Nevertheless, it is notable that the female patients, the patients with high BMI or the patients with low fasting serum glucose level are sensitive to the Lp-PLA2-promoting effects of AAP administration. All of the findings are likely to be a reference to clinical practice. The extent and the associated factors of increasing Lp-PLA2 levels and CVD risk in olanzapine, clozapine and quetiapine are discrepant. The possible effects of AAP on Lp-PLA2 in schizophrenia patients are involved in pro-inflammatory cytokines and hormones.
A limitation of the present study is the small size of the patients who received quetiapine or no medication, the deficiency of the patients who received ziprasidone or aripiprazole that had no weight gain/obesity side effects and the patients receiving AAP for 1 week or shorter. The other limitation is that the patients treated with clozapine had younger age of illness onset and longer duration of illness than those receiving no antipsychotics. Nevertheless, age of illness onset and duration of illness are not associated with Lp-PLA2 levels. Therefore, the difference had little selective potential bias.
